Observational studyActa neurologica Scandinavica2022
Long-term outcomes after aneurysmal subarachnoid hemorrhage: A prospective observational cohort study.
Observational study in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Acute glycemic variability and short-term mortality of patients with subarachnoid hemorrhage: a meta-analysis.Frontiers in neurologyPooled it
- Heterogeneity of Clazosentan Benefit after Aneurysmal Subarachnoid Hemorrhage Demonstrated in an Externally Validated Causal Policy Tree.Neurocritical care · 2026Article
- Cognition and Health-Related Quality of Life After aSAH: The Role of Objective and Subjective Impairment.Neurology international · 2026Article
- Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor.Headache · 2026Article
- Sleep and Cognitive Dysfunction in Subarachnoid Hemorrhage: A Scoping Review.Journal of clinical medicine · 2026Review
- Vitamin E reduces vasospasm in a rat subarachnoid hemorrhage model.Neurosurgical review · 2025Article
- Experimental study of the effects of diazepam on vasospasm in a subarachnoid rat model through pathological and biochemical analysis.Scientific reports · 2025Article
- Are Hippocampal Hypoperfusion and ATP Depletion Prime Movers in the Genesis of Alzheimer's Disease? A Review of Recent Pertinent Observations from Molecular Biology.International journal of molecular sciences · 2025Review
- Classification of life satisfaction by occupational gaps and its characteristics among older adults with care needs.Hong Kong journal of occupational therapy : HKJOT · 2024Article
- Neurobehavioral Impairments Predict Specific Cerebral Damage in Rat Model of Subarachnoid Hemorrhage.Translational stroke research · 2024Article
- Risk Factors and Clinical Significance of Ultra-Long-Term Microischemia After Intracranial Aneurysm Embolization.Neurology and therapy · 2024Article
- Safety of thrombectomy for medium vessel occlusions.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2024Article
- Neurobehavioral impairments predict specific cerebral damage in rat model of subarachnoid hemorrhage.Research square · 2023Article
- Long-term outcomes after aneurysmal subarachnoid hemorrhage: A prospective observational cohort study.Acta neurologica Scandinavica · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe survival rates for patients affected by aneurysmal subarachnoid hemorrhage (aSAH) have increased in recent years; however, many patients continue to develop cognitive dysfunctions that affect their quality of life. The commonly used outcome measures often fail to identify these cognitive dysfunctions. This study aimed to evaluate the long-term outcomes at 1 and 3 years after aSAH to assess changes over time and relate outcomes to patient characteristics and events during the acute phase. MATERIALS AND
methodsThis prospective observational study included patients that experienced aSAH. Patients were assessed according to the extended Glasgow Outcome Scale, Life Satisfaction Questionnaire, Mayo-Portland Adaptability inventory-4, and Mental Fatigue scale.
resultsPatients were assessed after 1 year (n = 62) and 3 years (n = 54). At 3 years, the extended Glasgow Outcome Scale score improved in 15% and worsened in 12% of the patients. Mental fatigue was observed in 57% of the patients at 1 year. Patients <60 years of age at the time of aSAH had more self-assessed problems, including pain/headache (p < .01), than patients >60 years of age. Patients with delayed cerebral ischemia during the acute phase reported more dissatisfaction at 3 years, whereas no significant result was seen at 1 year.
conclusionsCognitive dysfunction, especially mental fatigue, is common in patients with aSAH, which affects quality of life and recovery. Patient outcome is a dynamic process developing throughout years after aSAH, involving both improvement and deterioration. This study indicates the importance of longer follow-up periods with broad outcome assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.